Compare Ascendis Pharma A/S (ASND) vs iShares 20 Plus Year Treasury Bond ETF (TLT) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares 20 Plus Year Treasury Bond ETF — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while iShares 20 Plus Year Treasury Bond ETF trades at $84.34. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares 20 Plus Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | TLT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | — |
52-Week High | $277.18 | $92.06 |
52-Week Low | $163.32 | $83.02 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TLT, the iShares 20+ Year Treasury Bond ETF, trades at $84.47, showing minimal daily movement with a slight decline of 0.02%. Technical indicators signal a bearish trend, while recent news highlights investor comparisons with other bond ETFs amid fluctuating Treasury yields. The ETF maintains consistent dividend distributions, with recent payouts in 2026, but lacks disclosed fundamental ratios like P/E or ROE, focusing instead on its role in long-term U.S. government debt exposure.
The outlook for TLT hinges on interest rate trends and economic data, with potential gains if the Fed cuts rates but risks from persistent inflation or further hikes. Investor sentiment is mixed, weighing high yields against duration risk, making it sensitive to macroeconomic shifts rather than company-specific fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares 20 Plus Year Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index, and it will invest at least 90% of its assets in US Treasury securities that the advisor believes will help the fund track the underlying index. The underlying index measures the performance of public obligations of the US Treasury that have a remaining maturity greater than or equal to twenty years.
Read more on TLT →
